A Randomized, Double-Blind Trial Comparing Ceftobiprole Medocaril with Vancomycin plus Ceftazidime for the Treatment of Patients with Complicated Skin and Skin-Structure Infections

This publication has 19 references indexed in Scilit:

• Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection?
  Clinical Microbiology & Infection, 2007
• Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department
  New England Journal of Medicine, 2006
• Emergence of Community-Acquired Methicillin-Resistant Staphylococcus aureus USA 300 Clone as the Predominant Cause of Skin and Soft-Tissue Infections
  Annals of Internal Medicine, 2006
• Can β-lactams be re-engineered to beat MRSA?
  Clinical Microbiology & Infection, 2006
• Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
  Clinical Infectious Diseases, 2005
• Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin
  Antimicrobial Agents and Chemotherapy, 2005
• Comparative In Vitro Activity of Ceftobiprole against Staphylococci Displaying Normal and Small-Colony Variant Phenotypes
  Antimicrobial Agents and Chemotherapy, 2005
• Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus
  Antimicrobial Agents and Chemotherapy, 2005
• In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci
  Journal of Antimicrobial Chemotherapy, 2002
• In Vitro and In Vivo Properties of Ro 63-9141, a Novel Broad-Spectrum Cephalosporin with Activity against Methicillin-Resistant Staphylococci
  Antimicrobial Agents and Chemotherapy, 2001